Fig. 3

A 2-week therapeutic treatment with BLZ945 after a 5-week cuprizone intoxication period enhanced remyelination and increased the number of mature oligodendrocytes in cortex and striatum but not corpus callosum/external capsule compared to vehicle treatment. a Representative pictures from immunohistological stainings detecting myelin basic protein (MBP) and mature oligodendrocytes positive for GST-π in the cortex for the different treatment groups at week 7 (see Fig. 2a for the experimental setups and groups). b, c Corresponding quantitative analysis of the immunohistochemistry for MBP (stained area) and GST-π (number of positive cells) in the cortex and striatum normalized to values from control vehicle mice. d Representative pictures from immunohistological stainings detecting myelin oligondendrocyte glycoprotein (MOG) and mature oligodendrocytes positive for GST-π in the corpus callosum and external capsule for the different treatment groups at week 7. e Corresponding analysis of the immunohistochemistry for MOG (optical density, OD) and GST-π (number of positive cells) as well as OD analysis of Luxol fast blue (LFB) in the cc and ec. Values were normalized to those of control vehicle mice. Grey and black symbols indicate individual values from two independent experiments. Group sizes: control+vehicle (n = 7 from experiment 1, n = 6–7 from experiment 2), cuprizone+vehicle (n = 7 from experiment 1, n = 7 from experiment 2), cuprizone+BLZ945 (n = 7 from experiment 1, n = 5–6 from experiment 2). Data are shown as means±SEM. Scale bars: 200 μm (MBP and MOG), 100 μm (GST-π). Statistics (for combined experiments): Turkey’s multiple comparison test one-way ANOVA (*: p < 0.05, **: p < 0.01, ***: p < 0.001, ****: p < 0.0001, n.s.: not significant), cpz: cuprizone, cc: corpus callosum, ec: external capsule, OD: optical density